Alberto Ortiz

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7087973/alberto-ortiz-publications-by-year.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

661 68,229 84 253 h-index g-index citations papers 87,403 7.2 7.97 770 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
661	Sarcopenia assessed by 4-step EWGSOP2 in elderly hemodialysis patients: Feasibility and limitations <i>PLoS ONE</i> , 2022 , 17, e0261459	3.7	3
660	Fatty kidney: A possible future for chronic kidney disease research <i>European Journal of Clinical Investigation</i> , 2022 , e13748	4.6	О
659	Growth differentiation factor-15 (GDF-15) and syndecan-1 are potential biomarkers of cardiac and renal involvement in classical Fabry disease under enzyme replacement therapy <i>Kidney and Blood Pressure Research</i> , 2022 ,	3.1	1
658	Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study <i>Nephrology Dialysis Transplantation</i> , 2022 ,	4.3	2
657	Early glomerular filtration rate changes in living kidney donors and recipients: an example of renal plasticity <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 885-894	4.5	O
656	Reply Journal of Hypertension, 2022 , 40, 624-626	1.9	
655	CCN2 (Cellular Communication Network Factor 2) Deletion Alters Vascular Integrity and Function Predisposing to Aneurysm Formation <i>Hypertension</i> , 2022 , 79, e42-e55	8.5	2
654	Antifibrotic Agents for the Management of CKD: A Review <i>American Journal of Kidney Diseases</i> , 2022 ,	7.4	3
653	Use of chronic kidney disease blind spot to prevent cardiorenal outcomes <i>European Heart Journal</i> , 2022 , 43, 257-260	9.5	O
652	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 31-42	4.5	2
651	Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method <i>Journal of Nephrology</i> , 2022 , 1	4.8	1
650	The role of body mass index on IgA nephropathy prognosis: a systematic review and meta-analysis <i>International Urology and Nephrology</i> , 2022 , 1	2.3	
649	Growth differentiation factor-15 preserves Klotho expression in acute kidney injury and kidney fibrosis <i>Kidney International</i> , 2022 ,	9.9	2
648	Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 432-441	4.5	5
647	Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 397-406	4.5	3
646	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure: Position paper from the Cardiorenal Working Groups of the Spanish Society of Nephrology and the Spanish Society of Cardiology <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 865-872	4.5	1
645	The ERA Registry Annual Report 2019: summary and age comparisons <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 452-472	4.5	7

(2021-2022)

644	The Use of Healthy Eating Index 2015 and Healthy Beverage Index for Predicting and Modifying Cardiovascular and Renal Outcomes <i>Current Nutrition Reports</i> , 2022 , 1	6	О
643	Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum Clinical Journal of the American Society of Nephrology: CJASN, 2022,	6.9	O
642	Sarcopenia and Mortality in Older Hemodialysis Patients. <i>Nutrients</i> , 2022 , 14, 2354	6.7	1
641	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2021 , 41, 391-402	0.4	
640	The renal patient seen by non-renal physicians: the kidney embedded in the Pmilieu intlieur P. CKJ: Clinical Kidney Journal, 2021, 14, 1077-1087	4.5	
639	Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	8
638	Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease. <i>Journal of Nephrology</i> , 2021 , 34, 649-659	4.8	7
637	Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. <i>Toxicology and Applied Pharmacology</i> , 2021 , 414, 115412	4.6	7
636	Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1879-1885	4.5	4
635	Role of Klotho in the Development of Essential Hypertension. <i>Hypertension</i> , 2021 , 77, 740-750	8.5	9
634	Kidneys also speak Spanish. <i>Nefrologia</i> , 2021 , 41, 224-226	0.4	
633	TWEAK-Fn14 as a common pathway in the heart and the kidneys in cardiorenal syndrome. <i>Journal of Pathology</i> , 2021 , 254, 5-19	9.4	O
632	Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy. <i>Nefrologia</i> , 2021 , 41, 652-652	1.5	1
631	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	5
630	Urinary Growth Differentiation Factor-15 (GDF15) levels as a biomarker of adverse outcomes and biopsy findings in chronic kidney disease. <i>Journal of Nephrology</i> , 2021 , 34, 1819-1832	4.8	7
629	Phosphate, Microbiota and CKD. <i>Nutrients</i> , 2021 , 13,	6.7	3
628	Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?. <i>Hypertension</i> , 2021 , 77, 1029-1035	8.5	10
627	Hypertension in kidney transplantation: a consensus statement of the Phypertension and the kidneyPworking group of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021 , 39, 15	13 ⁻¹ 52	1 4

626	Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. <i>Mitochondrion</i> , 2021 , 58, 72-82	4.9	5
625	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	10
624	[Interleukin-17A: Possible mediator and therapeutic target in hypertension]. <i>Nefrologia</i> , 2021 , 41, 244-2	5:7 5	2
623	Interleukin-17A: Potential mediator and therapeutic target in hypertension. <i>Nefrologia</i> , 2021 , 41, 244-25	53.4	1
622	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. <i>Transplant International</i> , 2021 , 34, 1341-1359	3	2
621	Renin-angiotensin system and inflammation update. <i>Molecular and Cellular Endocrinology</i> , 2021 , 529, 111254	4.4	6
620	Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1061-1072	6.9	3
619	TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 191	3 ¹ 1932	3
618	Acute Kidney Injury is Aggravated in Aged Mice by the Exacerbation of Proinflammatory Processes. <i>Frontiers in Pharmacology</i> , 2021 , 12, 662020	5.6	4
617	A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas mice with proliferative lupus nephritis predicts low effect size. <i>Kidney International</i> , 2021 , 99, 1331-134	1 ^{9.9}	4
616	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2021 , 41, 391-402	1.5	1
615	Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies. <i>Journal of Nephrology</i> , 2021 , 34, 39-51	4.8	3
614	Bisphenol S is a haemodialysis-associated xenobiotic that is less toxic than bisphenol A. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1147-1155	4.5	3
613	The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. <i>Kidney International</i> , 2021 , 99, 986-998	9.9	37
612	Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1136-1146	4.5	О
611	A primer on metabolic memory: why existing diabesity treatments fail. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 756-767	4.5	O
610	Intravenous iron therapy and the cardiovascular system: risks and benefits. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1067-1076	4.5	2
609	Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 87-94	4.3	109

(2021-2021)

608	The effect of energy restriction on development and progression of chronic kidney disease: review of the current evidence. <i>British Journal of Nutrition</i> , 2021 , 125, 1201-1214	3.6	О
607	Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. <i>Acta Diabetologica</i> , 2021 , 58, 81-91	3.9	14
606	Podocyte and tubular involvement in AngioJet-induced kidney injury. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 424-428	4.5	4
605	Development and internal validation of a prediction model for hospital-acquired acute kidney injury. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 309-316	4.5	5
604	Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	4
603	Suboptimal personal protective equipment and SARS-CoV-2 infection in Nephrologists: a Spanish national survey. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1216-1221	4.5	3
602	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	7
601	Clinical Features of Asymptomatic SARS-CoV-2 Infection in Hemodialysis Patients. <i>Kidney and Blood Pressure Research</i> , 2021 , 46, 126-134	3.1	8
600	Sodiumglucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. <i>Journal of Hypertension</i> , 2021 , 39, 1090-1097	1.9	6
599	Effect of Coffee Consumption on Renal Outcome: A Systematic Review and Meta-Analysis of Clinical Studies. <i>Journal of Renal Nutrition</i> , 2021 , 31, 5-20	3	6
598	Mass Disasters and Burnout in Nephrology Personnel: From Earthquakes and Hurricanes to COVID-19 Pandemic. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 829-837	6.9	6
597	Nephrology in Spain 2021 , 639-655		O
596	Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	3
595	Belimumab in Lupus Nephritis. <i>New England Journal of Medicine</i> , 2021 , 384, 187	59.2	O
594	Undiagnosed cardiovascular risk factors in overweight and obese individuals: a low income country experience. <i>PeerJ</i> , 2021 , 9, e10870	3.1	1
593	Iohexol plasma clearance simplified by Dried Blood Spot (DBS) sampling to measure renal function in conscious mice. <i>Scientific Reports</i> , 2021 , 11, 4591	4.9	3
592	Dynamic assessment of interleukin-6 during hemodialysis and mortality in coronavirus disease-19. <i>Therapeutic Apheresis and Dialysis</i> , 2021 , 25, 908-916	1.9	4
591	Urinary Cyclophilin A as Marker of Tubular Cell Death and Kidney Injury. <i>Biomedicines</i> , 2021 , 9,	4.8	3

590	Estimated GFR Slope in Kidney Transplant Patients: When the Error Is Random. <i>Transplantation</i> , 2021 ,	1.8	1
589	EDTAKI: A Nephrology and Public Policy Committee (NPPC) Platform Call for More European Involvement in AKI. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	1
588	Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies. <i>Drugs</i> , 2021 , 81, 1467-1489	12.1	1
587	Role of Macrophages and Related Cytokines in Kidney Disease. Frontiers in Medicine, 2021 , 8, 688060	4.9	7
586	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. <i>Molecular Diagnosis and Therapy</i> , 2021 , 25, 563-576	4.5	1
585	Tasa de ultrafiltracifi horaria ajustada a peso corporal y mortalidad en hemodilisis. <i>Nefrologia</i> , 2021 , 41, 426-435	1.5	2
584	Aguascalientes: one of the hottest chronic kidney disease (CKD) hotspots in Mexico and a CKD of unknown aetiology mystery to be solved. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 2285-2294	4.5	1
583	Sodium-glucose cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. <i>Nephrology</i> , 2021 , 26, 1007-1017	2.2	2
582	Primary membranous nephropathy in the era of autoantibodies and biological therapies. <i>Medicina Claica (English Edition)</i> , 2021 , 157, 121-129	0.3	
581	Primary membranous nephropathy in the era of autoantibodies and biological therapies. <i>Medicina Clūica</i> , 2021 , 157, 121-129	1	1
580	Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T´cell immunity in naive and COVID-19 recovered individuals. <i>Cell Reports</i> , 2021 , 36, 109570	10.6	29
579	The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease. <i>Kidney International Reports</i> , 2021 , 6, 2392-2403	4.1	O
578	Verinurad/Febuxostat and Nephrotoxicity. American Journal of Kidney Diseases, 2021, 78, 468	7.4	1
577	Substitution of Sugar-Sweetened Beverages for Other Beverages: Can It Be the Next Step Towards Healthy Aging?. <i>Current Nutrition Reports</i> , 2021 , 1	6	1
576	Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review. <i>International Urology and Nephrology</i> , 2021 , 53, 1839-1849	2.3	1
575	Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	4
574	Brain dysfunction in tubular and tubulointerstitial kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	2
573	Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy. <i>Nefrologia</i> , 2021 , 41, 652-660	0.4	O

(2020-2021)

572	Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy <i>Drugs</i> , 2021 , 82, 109	12.1	O	
57 ¹	Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review <i>Tuberkuloz Ve Toraks</i> , 2021 , 69, 547-560	0.8	5	
570	Persistent acute renal failure in a patient infected with Plasmodium malariae: the importance of renal biopsy. <i>Nefrologia</i> , 2020 , 40, 571-573	0.4		
569	Ferroptosis and kidney disease. <i>Nefrologia</i> , 2020 , 40, 384-394	0.4	5	
568	Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype. <i>Molecular Genetics and Metabolism Reports</i> , 2020 , 25, 100670	1.8	3	
567	[Impact of the COVID-19 pandemic on Spanish Nephrology Services]. <i>Nefrologia</i> , 2020 , 40, 579-584	1.5	7	
566	Gender, Albuminuria and Chronic Kidney Disease Progression in Treated Diabetic Kidney Disease. Journal of Clinical Medicine, 2020 , 9,	5.1	2	
565	Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	17	
564	Statins: Could an old friend help in the fight against COVID-19?. <i>British Journal of Pharmacology</i> , 2020 , 177, 4873-4886	8.6	68	
563	SGLT2i and postglomerular vasodilation. <i>Kidney International</i> , 2020 , 97, 805-806	9.9	3	
562	Chronodisruption: A Poorly Recognized Feature of CKD. <i>Toxins</i> , 2020 , 12,	4.9	4	
561	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. Journal of Clinical Medicine, 2020 , 9,	5.1	14	
560	Ferroptosis and kidney disease. <i>Nefrologia</i> , 2020 , 40, 384-394	1.5	13	
559	TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 20	26 ¹ 2074	2 ⁵	
558	Effective Nephroprotection Against Acute Kidney Injury with a Star-Shaped Polyglutamate-Curcuminoid Conjugate. <i>Scientific Reports</i> , 2020 , 10, 2056	4.9	15	
557	The Role of PGC-1⊞nd Mitochondrial Biogenesis in Kidney Diseases. <i>Biomolecules</i> , 2020 , 10,	5.9	42	
				· '
556	Serum Levels and Removal by Haemodialysis and Haemodiafiltration of Tryptophan-Derived Uremic Toxins in ESKD Patients. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4	

554	Molecular pathways driving omeprazole nephrotoxicity. <i>Redox Biology</i> , 2020 , 32, 101464	11.3	12
553	Targeting the progression of chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2020 , 16, 269-288	14.9	158
552	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2020 , 8, 301-312	18.1	75
551	Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2020 , 395, 709-733	40	1021
550	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. <i>Europace</i> , 2020 , 22, 496-505	3.9	13
549	Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	17
548	Serum osmolarity as a potential predictor for contrast-induced nephropathy following elective coronary angiography. <i>International Urology and Nephrology</i> , 2020 , 52, 541-547	2.3	2
547	Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, i13-i23	4.3	13
546	Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. <i>Angiology</i> , 2020 , 71, 315-323	2.1	13
545	Albuminuria Downregulation of the Anti-Aging Factor Klotho: The Missing Link Potentially Explaining the Association of Pathological Albuminuria with Premature Death. <i>Advances in Therapy</i> , 2020 , 37, 62-72	4.1	12
544	Machine learning analysis of serum biomarkers for cardiovascular risk assessment in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2020 , 13, 631-639	4.5	2
543	Impact of COVID-19 pandemic in Spanish Nephrology Servicesservices impact of the pandemic on COVID-19 Spanish Nephrology Services. <i>Nefrologia</i> , 2020 , 40, 579-584	0.4	1
542	Protective Role of Nrf2 in Renal Disease. <i>Antioxidants</i> , 2020 , 10,	7.1	10
541	IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis. <i>Biomolecules</i> , 2020 , 10,	5.9	3
540	Inflammation both increases and causes resistance to FGF23 in normal and uremic rats. <i>Clinical Science</i> , 2020 , 134, 15-32	6.5	14
539	Coronavirus disease 2019 in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2020 , 13, 297-306	4.5	29
538	Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. <i>CKJ: Clinical Kidney Journal</i> , 2020 , 13, 913-925	4.5	5
537	Urine proteomics for prediction of disease progression in patients with IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	9

(2019-2020)

536	A sudden decrease in serum creatinine and estimated glomerular filtration rate: clinical implications of administrative gender assignment in transgender persons. <i>CKJ: Clinical Kidney Journal</i> , 2020 , 13, 1107-1108	4.5	О	
535	Design and optimization strategies for the development of new drugs that treat chronic kidney disease. <i>Expert Opinion on Drug Discovery</i> , 2020 , 15, 101-115	6.2	4	
534	Urinary transferrin pre-emptively identifies the risk of renal damage posed by subclinical tubular alterations. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 121, 109684	7.5	11	
533	An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. <i>CKJ: Clinical Kidney Journal</i> , 2020 , 13, 981-993	4.5	16	
532	Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6	
531	Low Intracellular Water, Overhydration, and Mortality in Hemodialysis Patients. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1	
530	Lyso-Gb3 Increases IIB Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3	
529	Givosiran for Acute Intermittent Porphyria. New England Journal of Medicine, 2020, 383, 1989	59.2	6	
528	Hematuria Is Associated with More Severe Acute Tubulointerstitial Nephritis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1	
527	The Spectrum of Clinical and Serological Features of COVID-19 in Urban Hemodialysis Patients. Journal of Clinical Medicine, 2020 , 9,	5.1	9	
526	Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107707	3.2	7	
525	Sweet dreams: therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin and diabetic nephropathy. <i>CKJ: Clinical Kidney Journal</i> , 2020 , 13, 522-530	4.5	1	
524	Resistant hypertension: new insights and therapeutic perspectives. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 188-193	6.4	4	
523	Loss of NLRP6 expression increases the severity of acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 587-598	4.3	12	
522	The Contribution of Histone Crotonylation to Tissue Health and Disease: Focus on Kidney Health. <i>Frontiers in Pharmacology</i> , 2020 , 11, 393	5.6	13	
521	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	27	
520	The role of endothelial glycocalyx in health and disease. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 611-619	4.5	42	
519	Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 629-638	4.5	15	

518	Interleukin 17A Participates in Renal Inflammation Associated to Experimental and Human Hypertension. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1015	5.6	25
517	Antidiuretic Hormone and Serum Osmolarity Physiology and Related Outcomes: What Is Old, What Is New, and What Is Unknown?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5406-5420	5.6	13
516	Reactions to Synthetic Membranes Dialyzers: Is there an Increase in Incidence?. <i>Kidney and Blood Pressure Research</i> , 2019 , 44, 907-914	3.1	8
515	Positive/retained SDHB immunostaining in renal cell carcinomas associated to germline SDHB-deficiency: case report. <i>Diagnostic Pathology</i> , 2019 , 14, 42	3	3
514	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 313-321	4.5	22
513	Diabetes-mediated promotion of colon mucosa carcinogenesis is associated with mitochondrial dysfunction. <i>Molecular Oncology</i> , 2019 , 13, 1887-1897	7.9	5
512	MAP3K kinases and kidney injury. <i>Nefrologia</i> , 2019 , 39, 568-580	1.5	10
511	Diagnostic Utility of Exome Sequencing for Kidney Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 2078	59.2	10
510	Criteria for classification of protein-energy wasting in dialysis patients: impact on prevalence. <i>British Journal of Nutrition</i> , 2019 , 121, 1271-1278	3.6	12
509	Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. <i>FASEB Journal</i> , 2019 , 33, 8961-8975	0.9	72
508	Questioning the Safety of Calcidiol in Hemodialysis Patients. <i>Nutrients</i> , 2019 , 11,	6.7	2
507	PGC-1Edeficiency causes spontaneous kidney inflammation and increases the severity of nephrotoxic AKI. <i>Journal of Pathology</i> , 2019 , 249, 65-78	9.4	41
506	Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	25
505	The new , 4 years later. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 1-5	4.5	O
504	Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 923-933	4.3	13
503	The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. <i>Nefrologia</i> , 2019 , 39, 29-34	0.4	11
502	Burden, access and disparities in kidney disease: chronic kidney disease hotspots and progress one step at a time. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 157-159	4.5	3
501	Clarifying the concept of chronic kidney disease for non-nephrologists. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 258-261	4.5	22

500	NIK as a Druggable Mediator of Tissue Injury. <i>Trends in Molecular Medicine</i> , 2019 , 25, 341-360	11.5	13
499	Spanish multidisciplinary clinical practice guidelines for Anderson Habry disease in adults. I. Method and recommendations. <i>Revista Cl&#x00ed;nica Espan&#x00f5;la, 2019</i> , 219, 200-207	0.5	
498	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 208-230	4.3	88
497	Proteomics for Clinical Assessment of Kidney Disease. <i>Proteomics - Clinical Applications</i> , 2019 , 13, e1900	0904	2
496	Sarcopenia in CKD: a roadmap from basic pathogenetic mechanisms to clinical trials. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 110-112	4.5	19
495	MYH9-related disease: it does exist, may be more frequent than you think and requires specific therapy. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 488-493	4.5	8
494	Lyso-Gb3 modulates the gut microbiota and decreases butyrate production. <i>Scientific Reports</i> , 2019 , 9, 12010	4.9	9
493	Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 1938-1966	9.4	69
492	ERT impact on left ventricular mass in Fabry disease. <i>Molecular Genetics and Metabolism Reports</i> , 2019 , 20, 100485	1.8	
491	Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2368-2383	6.7	26
490	Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury. <i>Frontiers in Pharmacology</i> , 2019 , 10, 740	5.6	21
489	Dietary Care for ADPKD Patients: Current Status and Future Directions. <i>Nutrients</i> , 2019 , 11,	6.7	11
488	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , 2019 , 574, 353-	3 58 .4	87
487	The chaos of hypertension guidelines for chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 771-777	4.5	7
486	Molecular evidence of field cancerization initiated by diabetes in colon cancer patients. <i>Molecular Oncology</i> , 2019 , 13, 857-872	7.9	8
485	A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 861-870	4.5	8
484	MAP3K kinases and kidney injury. <i>Nefrologia</i> , 2019 , 39, 568-580	0.4	3
483	The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. <i>Nefrologia</i> , 2019 , 39, 29-34	1.5	25

482	MAGE genes in the kidney: identification of MAGED2 as upregulated during kidney injury and in stressed tubular cells. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1498-1507	4.3	11
481	Multilayered Interplay Between Fructose and Salt in Development of Hypertension. <i>Hypertension</i> , 2019 , 73, 265-272	8.5	10
480	Air pollution and kidney disease: review of current evidence. CKJ: Clinical Kidney Journal, 2019, 12, 19-3	24.5	47
479	Advances in understanding the role of angiotensin-regulated proteins in kidney diseases. <i>Expert Review of Proteomics</i> , 2019 , 16, 77-92	4.2	12
478	Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 420-426	4.5	16
477	Potential Dangers of Serum Urate-Lowering Therapy. American Journal of Medicine, 2019, 132, 457-467	2.4	25
476	Working towards novel albuminuria endpoints in chronic kidney disease. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 80-82	18.1	1
475	The effect of chronic kidney disease on lipid metabolism. <i>International Urology and Nephrology</i> , 2019 , 51, 265-277	2.3	18
474	The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts. <i>Molecular Genetics and Metabolism</i> , 2019 , 126, 224-235	3.7	33
473	Podocyturia: why it may have added value in rare diseases. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 49-52	4.5	6
472	Inflammation in Diabetic Kidney Disease. <i>Nephron</i> , 2019 , 143, 12-16	3.3	65
471	Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry. <i>JIMD Reports</i> , 2018 , 38, 45-51	1.9	11
470	Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 577-584	6.9	7
469	Phenytoin inhibits necroptosis. <i>Cell Death and Disease</i> , 2018 , 9, 359	9.8	30
468	Nephrotoxicity 2018 , 169-184		2
467	Fabry disease revisited: Management and treatment recommendations for adult patients. <i>Molecular Genetics and Metabolism</i> , 2018 , 123, 416-427	3.7	215
466	Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. <i>Molecular Genetics & Commic Medicine</i> , 2018 , 6, 492	2.3	46
465	CKD 2018 , 319-326		

464	Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields. <i>Cell Death and Disease</i> , 2018 , 9, 118	9.8	9
463	Albumin downregulates Klotho in tubular cells. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1712-172	.2 4.3	50
462	Paricalcitol and albuminuria: tread carefully. Lancet Diabetes and Endocrinology, the, 2018, 6, 3-5	18.1	6
461	Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. <i>Drugs</i> , 2018 , 78, 215-229	12.1	22
460	Gremlin activates the Notch pathway linked to renal inflammation. <i>Clinical Science</i> , 2018 , 132, 1097-111	156.5	17
459	Enzyme replacement therapy dose and Fabry nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1284-1289	4.3	6
458	Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 2156-2164	4.3	22
457	Targeting of regulated necrosis in kidney disease. <i>Nefrologia</i> , 2018 , 38, 125-135	0.4	11
456	TWEAK and RIPK1 mediate a second wave of cell death during AKI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 4182-4187	11.5	64
455	Targeting epigenetic DNA and histone modifications to treat kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1875-1886	4.3	58
454	Targeting of regulated necrosis in kidney disease. <i>Nefrologia</i> , 2018 , 38, 125-135	1.5	23
453	Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression. <i>Toxins</i> , 2018 , 10,	4.9	62
452	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). <i>Toxins</i> , 2018 , 10,	4.9	19
451	Identification and Chemical Characterization of Insoluble Contaminants in Hemodialysis Water Treatment. <i>Water (Switzerland)</i> , 2018 , 10, 486	3	Ο
450	CCL20 blockade increases the severity of nephrotoxic folic acid-induced acute kidney injury. <i>Journal of Pathology</i> , 2018 , 246, 191-204	9.4	16
449	The burden of disease in Spain: Results from the Global Burden of Disease 2016. <i>Medicina Claica</i> , 2018 , 151, 171-190	1	55
448	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, ii4-ii14	4.3	52
447	Research update for articles published in EJCI in 2016. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e13016	4.6	

446	Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development. <i>CKJ: Clinical Kidney Journal</i> , 2018 , 11, 491-495	4.5	11
445	Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease. <i>Diabetes Care</i> , 2018 , 41, 1817-1820	14.6	36
444	European expert consensus statement on therapeutic goals in Fabry disease. <i>Molecular Genetics and Metabolism</i> , 2018 , 124, 189-203	3.7	71
443	Influence of dialysis membrane composition on plasma bisphenol A levels during online hemodiafiltration. <i>PLoS ONE</i> , 2018 , 13, e0193288	3.7	8
442	Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 255-263	3.9	27
441	TWEAK increases CD74 expression and sensitizes to DDT proinflammatory actions in tubular cells. <i>PLoS ONE</i> , 2018 , 13, e0199391	3.7	11
440	Connective tissue growth factor induces renal fibrosis via epidermal growth factor receptor activation. <i>Journal of Pathology</i> , 2018 , 244, 227-241	9.4	35
439	Bisphenol A is an exogenous toxin that promotes mitochondrial injury and death in tubular cells. <i>Environmental Toxicology</i> , 2018 , 33, 325-332	4.2	30
438	Bleeding in advanced CKD patients on antithrombotic medication - A critical appraisal. <i>Pharmacological Research</i> , 2018 , 129, 535-543	10.2	10
437	Neonatal, infant, and under-5 mortality and morbidity burden in the Eastern Mediterranean region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018 , 63, 63-77	4	10
436	Adolescent health in the Eastern Mediterranean Region: findings from the global burden of disease 2015 study. <i>International Journal of Public Health</i> , 2018 , 63, 79-96	4	8
435	Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018 , 63, 177-186	4	19
434	Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018 , 392, 1684-1735	40	483
433	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018 , 392, 1736-1788	40	2850
432	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018 , 392, 1923-1994	40	1964
431	Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018 , 392, 1995-2051	40	189
430	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018 , 392, 1789-1858	40	4524
429	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018 , 392, 2091-2138	40	210

428	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018 , 392, 1859-1922	40	1283
427	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750	16.4	3642
426	Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole. <i>CKJ: Clinical Kidney Journal</i> , 2018 , 11, 688-690	4.5	4
425	Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium. <i>Frontiers in Physiology</i> , 2018 , 9, 1643	4.6	3
424	Incidence of Hypersensitivity Reactions During Hemodialysis. <i>Kidney and Blood Pressure Research</i> , 2018 , 43, 1472-1478	3.1	8
423	Gremlin Regulates Tubular Epithelial to Mesenchymal Transition via VEGFR2: Potential Role in Renal Fibrosis. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1195	5.6	21
422	Lipid management in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2018 , 14, 727-74	1 9 14.9	82
421	Cardiovascular Safety of Febuxostat. <i>New England Journal of Medicine</i> , 2018 , 379, 1584	59.2	3
420	Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease. <i>Scientific Reports</i> , 2018 , 8, 15940	4.9	25
419	Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. <i>BMC Medicine</i> , 2018 , 16, 158	11.4	12
418	Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. <i>Diabetic Medicine</i> , 2018 , 35, 1375-1382	3.5	19
417	Women and renal replacement therapy in Europe: lower incidence, equal access to transplantation, longer survival than men. <i>CKJ: Clinical Kidney Journal</i> , 2018 , 11, 1-6	4.5	14
416	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018 , 391, 2236-2271	40	381
415	Salt Intake and Immunity. <i>Hypertension</i> , 2018 , 72, 19-23	8.5	12
414	Capillary rarefaction from the kidney point of view. CKJ: Clinical Kidney Journal, 2018, 11, 295-301	4.5	30
413	Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. <i>New England Journal of Medicine</i> , 2018 , 378, 2540-2541	59.2	49
412	The Future of IL-1 Targeting in Kidney Disease. <i>Drugs</i> , 2018 , 78, 1073-1083	12.1	10
411	Podocytes are new cellular targets of haemoglobin-mediated renal damage. <i>Journal of Pathology</i> , 2018 , 244, 296-310	9.4	32

410	Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid-Induced AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 218-229	12.7	199
409	Diagnosis and treatment of Fabry disease. <i>Medicina Claica</i> , 2017 , 148, 132-138	1	13
408	Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells. <i>Scientific Reports</i> , 2017 , 7, 41510	4.9	17
407	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the	4.3	79
406	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 2167-2179	12.7	127
405	The systemic nature of CKD. <i>Nature Reviews Nephrology</i> , 2017 , 13, 344-358	14.9	152
404	Colchicine in Renal Medicine: New Virtues of an Ancient Friend. <i>Blood Purification</i> , 2017 , 43, 125-135	3.1	14
403	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the	1.9	35
402	Hyponatraemia diagnosis and treatment clinical practice guidelines. <i>Nefrologia</i> , 2017 , 37, 370-380	1.5	11
401	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017 , 390, 231-266	40	352
400	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1967-1976	4.3	11
399	Child and Adolescent Health From 1990 to 2015: Findings From the Global Burden of Diseases, Injuries, and Risk Factors 2015 Study. <i>JAMA Pediatrics</i> , 2017 , 171, 573-592	8.3	216
398	Diagnosis and treatment of Fabry disease. <i>Medicina Claica (English Edition)</i> , 2017 , 148, 132-138	0.3	О
397	Tweak up-regulates endothelin-1 system in mouse and human endothelial cells. <i>Cardiovascular Research</i> , 2017 , 113, 207-221	9.9	18
396	Urine metabolomics insight into acute kidney injury point to oxidative stress disruptions in energy generation and HS availability. <i>Journal of Molecular Medicine</i> , 2017 , 95, 1399-1409	5.5	24
395	Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2017 , 125, 8-13	2.8	17
394	Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease. <i>International Journal of Nephrology</i> , 2017 , 2017, 1287289	1.7	5
393	Impact of post-dialysis calcium level on ex vivo rat aortic wall calcification. <i>PLoS ONE</i> , 2017 , 12, e01837	3 <u>0</u> .7	6

392	Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase. <i>CKJ: Clinical Kidney Journal</i> , 2017 , 10, 188-191	4.5	12
391	Does wealth make health? Cherchez la renal replacement therapy. <i>CKJ: Clinical Kidney Journal</i> , 2017 , 10, 45-48	4.5	3
390	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1084-1150	40	421
389	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1260-1344	40	1152
388	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1151-1210	40	2542
387	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1211-1259	40	3432
386	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1345-1422	40	1378
385	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1423-1459	40	224
384	Reply. <i>Medicina Clūica</i> , 2017 , 149, 271-272	1	1
383	Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?. <i>Scientific Reports</i> , 2017 , 7, 16915	4.9	39
383		4.9	39
	Scientific Reports, 2017 , 7, 16915	4.9	
382	Scientific Reports, 2017, 7, 16915 Resistant Hypertension in Elderly People with Chronic Kidney Disease 2017, 183-193 Bcl3: a regulator of NF-B inducible by TWEAK in acute kidney injury with anti-inflammatory and		
382	Resistant Hypertension in Elderly People with Chronic Kidney Disease 2017, 183-193 Bcl3: a regulator of NF-B inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells. Experimental and Molecular Medicine, 2017, 49, e352	12.8	28
382 381 380	Resistant Hypertension in Elderly People with Chronic Kidney Disease 2017, 183-193 Bcl3: a regulator of NF-B inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells. Experimental and Molecular Medicine, 2017, 49, e352 Translational science in chronic kidney disease. Clinical Science, 2017, 131, 1617-1629 Kidney Injury Marker 1 and Neutrophil Gelatinase-Associated Lipocalin in Chronic Kidney Disease.	12.8 6.5	28
382 381 380 379	Resistant Hypertension in Elderly People with Chronic Kidney Disease 2017, 183-193 Bcl3: a regulator of NF-B inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells. Experimental and Molecular Medicine, 2017, 49, e352 Translational science in chronic kidney disease. Clinical Science, 2017, 131, 1617-1629 Kidney Injury Marker 1 and Neutrophil Gelatinase-Associated Lipocalin in Chronic Kidney Disease. Nephron, 2017, 136, 263-267 Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental	12.86.53.3	28 13 29
382 381 380 379 378	Resistant Hypertension in Elderly People with Chronic Kidney Disease 2017, 183-193 Bcl3: a regulator of NF-B inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells. Experimental and Molecular Medicine, 2017, 49, e352 Translational science in chronic kidney disease. Clinical Science, 2017, 131, 1617-1629 Kidney Injury Marker 1 and Neutrophil Gelatinase-Associated Lipocalin in Chronic Kidney Disease. Nephron, 2017, 136, 263-267 Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage. Journal of the American Society of Nephrology: JASN, 2017, 28, 504-519 Early Macrophage Infiltration and Sustained Inflammation in Kidneys From Deceased Donors Are	12.8 6.5 3.3 12.7	28 13 29 39

374	Mitogen-Activated Protein Kinase 14 Promotes AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 823-836	12.7	22
373	Lesinurad: what the nephrologist should know. <i>CKJ: Clinical Kidney Journal</i> , 2017 , 10, 679-687	4.5	21
372	Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease. <i>Nutrients</i> , 2017 , 9,	6.7	48
371	Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son". <i>Toxins</i> , 2017 , 9,	4.9	43
370	2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. <i>Oncotarget</i> , 2017 , 8, 18456-18485	3.3	84
369	Colon cancer modulation by a diabetic environment: A single institutional experience. <i>PLoS ONE</i> , 2017 , 12, e0172300	3.7	5
368	Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. <i>PLoS ONE</i> , 2017 , 12, e0173358	3.7	52
367	A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients. <i>PLoS ONE</i> , 2017 , 12, e0173831	3.7	9
366	Designing a Method with Physician Participation to Assess and Improve Quality of Healthcare in Otolaryngology. <i>Journal of International Advanced Otology</i> , 2017 , 13, 128-135	1.1	
365	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 2079-2089	4.3	44
364	Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification. <i>Expert Opinion on Therapeutic Targets</i> , 2016 , 20, 89-105	6.4	33
363	Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. <i>Molecular Genetics and Metabolism</i> , 2016 , 119, 151-9	3.7	22
362	PCSK9 in diabetic kidney disease. European Journal of Clinical Investigation, 2016, 46, 779-86	4.6	16
361	Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. <i>Scientific Reports</i> , 2016 , 6, 27915	4.9	61
360	HIV and kidney diseases: 35 years of history and consequences. CKJ: Clinical Kidney Journal, 2016, 9, 777	2 <i>-3</i> 7. 8 31	35
359	TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFB. <i>Cell Death and Disease</i> , 2016 , 7, e2305	9.8	31
358	Non-canonical NF B activation promotes chemokine expression in podocytes. <i>Scientific Reports</i> , 2016 , 6, 28857	4.9	23
357	Circulating CXCL16 in Diabetic Kidney Disease. <i>Kidney and Blood Pressure Research</i> , 2016 , 41, 663-671	3.1	16

(2016-2016)

Out of the TWEAKlight: Elucidating the Role of Fn14 and TWEAK in Acute Kidney Injury. <i>Seminars in Nephrology</i> , 2016 , 36, 189-98	4.8	22
How should we analyze and present mortality in our patients?: A multicentre GCDP experience. <i>Nefrologia</i> , 2016 , 36, 149-55	1.5	2
Small vessel microembolization and acute glomerulonephritis following infection of aesthetic filler implants. <i>Diagnostic Pathology</i> , 2016 , 11, 2	3	2
Targeting inflammation in diabetic kidney disease: early clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 1045-58	5.9	52
NF B iz protein downregulation in acute kidney injury: Modulation of inflammation and survival in tubular cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016 , 1862, 635-646	6.9	19
Focus on renal congestion in heart failure. <i>CKJ: Clinical Kidney Journal</i> , 2016 , 9, 39-47	4.5	52
Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. <i>Cytokine and Growth Factor Reviews</i> , 2016 , 28, 71-7	17.9	19
Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. <i>International Urology and Nephrology</i> , 2016 , 48, 1129-36	2.3	17
Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events. <i>Calcified Tissue International</i> , 2016 , 99, 121-30	3.9	18
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 337-48	4.3	150
Atherosclerotic renal artery stenosis in the post-CORAL era part 1: the renal penumbra concept and next-generation functional diagnostic imaging. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 360-7		9
Atherosclerotic renal artery stenosis in the post-CORAL era part 2: new directions in Transcatheter Nephron Salvage following flawed revascularization trials. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 368-77		8
The Choice of Hemodialysis Membrane Affects Bisphenol A Levels in Blood. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 1566-74	12.7	37
The inflammatory cytokine TWEAK decreases PGC-1\(\hat{\text{Pe}}\) xpression and mitochondrial function in acute kidney injury. <i>Kidney International</i> , 2016 , 89, 399-410	9.9	74
Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. <i>Journal of Bone and Mineral Metabolism</i> , 2016 , 34, 587-98	2.9	10
Apoptosis inducing factor (AIF) mediates lethal redox stress induced by menadione. <i>Oncotarget</i> , 2016 , 7, 76496-76507	3.3	9
Increased urinary CD80 excretion and podocyturia in Fabry disease. <i>Journal of Translational Medicine</i> , 2016 , 14, 289	8.5	20
The Prevalence of Fabry Disease in Patients with Chronic Kidney Disease in Turkey: The TURKFAB	3.1	16
	Nephrology, 2016, 36, 189-98 How should we analyze and present mortality in our patients?: A multicentre CCDP experience. Nefrologia, 2016, 36, 149-55 Small vessel microembolization and acute glomerulonephritis following infection of aesthetic filler implants. Diagnostic Pathology, 2016, 11, 2 Targeting inflammation in diabetic kidney disease: early clinical trials. Expert Opinion on Investigational Drugs, 2016, 25, 1045-58 NFBiz protein downregulation in acute kidney injury: Modulation of inflammation and survival in tubular cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 635-646 Focus on renal congestion in heart failure. CKJ: Clinical Kidney Journal, 2016, 9, 39-47 Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. Cytokine and Growth Factor Reviews, 2016, 28, 71-7 Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. International Urology and Nephrology, 2016, 48, 1129-36 Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events. Calcified Tissue International, 2016, 99, 121-30 Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 2016, 31, 337-48 Atherosclerotic renal artery stenosis in the post-CORAL era part 1: the renal penumbra concept and next-generation Functional diagnostic imaging. Journal of the American Society of Hypertension, 2016, 10, 360-7 The Choice of Hemodialysis Membrane Affects Bisphenol A Levels in Blood. Journal of the American Society of Phypertension, 2016, 10, 360-7 The inflammatory cytokine TWEAK decreases PGC-1fexpression and mitochondrial function in acute kidney injury. Kidney International, 2016, 89, 399-410 Important abnormalities of bone mineral metabolism are present in pat	How should we analyze and present mortality in our patients?: A multicentre GCDP experience. Nefrologia, 2016, 36, 149-55 Small vessel microembolization and acute glomerulonephritis following infection of aesthetic filler implants. Diagnostic Pathology, 2016, 11, 2 Targeting inflammation in diabetic kidney disease: early clinical trials. Expert Opinion on Investigational Drugs, 2016, 25, 1045-58 NFBiz protein downregulation in acute kidney injury: Modulation of inflammation and survival in tubular cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 635-646 Focus on renal congestion in heart failure. CKJ: Clinical Kidney Journal, 2016, 9, 39-47 Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. Cytokine and Growth Factor Reviews, 2016, 28, 71-7 Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. International Urology and Nephrology, 2016, 48, 1129-36 Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events. Calcified Tissue International, 2016, 99, 121-30 Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 2015, 31, 337-48 Atherosclerotic renal artery stenosis in the post-CORAL era part 1: the renal penumbra concept and next-generation functional diagnostic imaging. Journal of the American Society of Hypertension, 2016, 10, 369-7 The Choice of Hemodialysis Membrane Affects Bisphenol A Levels in Blood. Journal of the American Society of Phypertension, 2016, 10, 368-77 The Choice of Hemodialysis Membrane Affects Bisphenol A Levels in Blood. Journal of the American Society of Phypertension, 2016, 10, 368-77 The Choice of Hemodialysis Membrane Affects Bisphenol A Levels in Blood. Journal of the American Society of

338	Urinary Kininogen-1 and Retinol binding protein-4 respond to Acute Kidney Injury: predictors of patient prognosis?. <i>Scientific Reports</i> , 2016 , 6, 19667	4.9	14
337	Time to treatment benefit for adult patients with Fabry disease receiving agalsidase [Idata from the Fabry Registry. <i>Journal of Medical Genetics</i> , 2016 , 53, 495-502	5.8	67
336	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. <i>BMJ Open</i> , 2016 , 6, e010310	3	92
335	Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, F1329-F1340	4.3	40
334	Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis. <i>CKJ: Clinical Kidney Journal</i> , 2016 , 9, 381-6	4.5	10
333	PrEFiNe Plan: Strategic plan for Fabry diseases in Nephrology. <i>Nefrologia</i> , 2016 , 36, 376-80	1.5	3
332	Chronicity following ischaemia-reperfusion injury depends on tubular-macrophage crosstalk involving two tubular cell-derived CSF-1R activators: CSF-1 and IL-34. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1409-16	4.3	11
331	Clinical management of the uraemic syndrome in chronic kidney disease. <i>Lancet Diabetes and Endocrinology,the</i> , 2016 , 4, 360-73	18.1	57
330	Atrial fibrillation in chronic kidney disease. European Journal of Internal Medicine, 2016, 33, 3-13	3.9	7
329	Hypertension in Chronic Kidney Disease Part 1: Out-of-Office Blood Pressure Monitoring: Methods, Thresholds, and Patterns. <i>Hypertension</i> , 2016 , 67, 1093-101	8.5	40
328	Hypertension in Chronic Kidney Disease Part 2: Role of Ambulatory and Home Blood Pressure Monitoring for Assessing Alterations in Blood Pressure Variability and Blood Pressure Profiles. <i>Hypertension</i> , 2016 , 67, 1102-10	8.5	59
327	Histone lysine crotonylation during acute kidney injury in mice. <i>DMM Disease Models and Mechanisms</i> , 2016 , 9, 633-45	4.1	64
326	Creatinine Clearance Is Not Equal to Glomerular Filtration Rate and Cockcroft-Gault Equation Is Not Equal to CKD-EPI Collaboration Equation. <i>American Journal of Medicine</i> , 2016 , 129, 1259-1263	2.4	36
325	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1603-1658	40	1216
324	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1459-1544	40	3525
323	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1545-1602	40	3801
322	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1659-1724	40	2431
321	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1813-1850	40	302

320	Peritoneal Dialysis Can Be an Option for Dominant Polycystic Kidney Disease: an Observational Study. <i>Peritoneal Dialysis International</i> , 2015 , 35, 530-6	2.8	17
319	Albumin-induced apoptosis of tubular cells is modulated by BASP1. Cell Death and Disease, 2015, 6, e16	5 49 .8	28
318	Lyso-Gb3 activates Notch1 in human podocytes. Human Molecular Genetics, 2015, 24, 5720-32	5.6	77
317	Healthcare-associated infections: new challenges looking for answers. <i>CKJ: Clinical Kidney Journal</i> , 2015 , 8, 100-1	4.5	1
316	Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function. <i>Therapeutic Advances in Drug Safety</i> , 2015 , 6, 166-76	3.5	27
315	Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKD. <i>Kidney International</i> , 2015 , 88, 194	9.9	5
314	Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect. <i>Journal of Leukocyte Biology</i> , 2015 , 98, 257-69	6.5	27
313	Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. <i>Hypertension</i> , 2015 , 66, 3-9	8.5	21
312	Biocompatibility reduces inflammation-induced apoptosis in mesothelial cells exposed to peritoneal dialysis fluid. <i>Blood Purification</i> , 2015 , 39, 200-209	3.1	10
311	Angiotensin II, via angiotensin receptor type 1/nuclear factor- B activation, causes a synergistic effect on interleukin-1-Induced inflammatory responses in cultured mesangial cells. <i>JRAAS</i> - <i>Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015 , 16, 23-32	3	19
310	Designing drugs that combat kidney damage. Expert Opinion on Drug Discovery, 2015, 10, 541-56	6.2	24
309	Translational value of animal models of kidney failure. <i>European Journal of Pharmacology</i> , 2015 , 759, 205-20	5.3	52
308	A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study. <i>CKJ: Clinical Kidney Journal</i> ,	4.5	34
307	2015, 8, 503-10 Phosphodiesterase type 5 inhibitors and kidney disease. <i>International Urology and Nephrology</i> , 2015, 47, 1521-8	2.3	25
306	Timing of eculizumab therapy for C3 glomerulonephritis. CKJ: Clinical Kidney Journal, 2015, 8, 449-52	4.5	13
305	IRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015 , 1853, 3224-34	4.9	22
304	The double challenge of resistant hypertension and chronic kidney disease. <i>Lancet, The</i> , 2015 , 386, 158	8 - 28	108
303	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015 , 386, 2145-91	40	1203

302	Use of sevelamer in chronic kidney disease: beyond phosphorus control. <i>Nefrologia</i> , 2015 , 35, 207-17	1.5	12
301	The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. <i>Molecular Genetics and Metabolism</i> , 2015 , 114, 248-58	3.7	59
300	Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 385, 117-71	40	4599
299	The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF- B pathway and proinflammatory factors in vascular smooth muscle cells. <i>Antioxidants and Redox Signaling</i> , 2015 , 22, 29-47	8.4	23
298	Finat Obscure Object of Desire in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 394-400	4.3	3
297	Klotho Prevents NF B Translocation and Protects Endothelial Cell From Senescence Induced by Uremia. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015 , 70, 1198-209	6.4	56
296	Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 5873-4	4.4	1
295	Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. <i>Journal of Clinical Medicine</i> , 2015 , 4, 1325-47	5.1	44
294	CD74 in Kidney Disease. Frontiers in Immunology, 2015 , 6, 483	8.4	14
293	Modifiable risk factors for increased arterial stiffness in outpatient nephrology. <i>PLoS ONE</i> , 2015 , 10, e0123903	3.7	3
292	Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells. <i>BioMed Research International</i> , 2015 , 2015, 783538	3	17
291	TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2. <i>Mediators of Inflammation</i> , 2015 , 2015, 506041	4.3	15
290	Pathogenesis of glomerular haematuria. World Journal of Nephrology, 2015, 4, 185-95	3.6	28
289	Welcome to the new ckj: an open-access resource integrating clinical, translational and educational research into clinical practice. <i>CKJ: Clinical Kidney Journal</i> , 2015 , 8, 1-2	4.5	1
288	Translational nephrology: what translational research is and a birdß-eye view on translational research in nephrology. <i>CKJ: Clinical Kidney Journal</i> , 2015 , 8, 14-22	4.5	18
287	Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. <i>Molecular Genetics and Metabolism</i> , 2015 , 114, 242-7	3.7	34
286	Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes. <i>Translational Research</i> , 2015 , 166, 474-484.e4	11	43
285	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015 , 386, 743-800	40	3802

(2014-2015)

284	2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs. <i>CKJ: Clinical Kidney Journal</i> , 2015 , 8, 243-7	4.5	11
283	Use of sevelamer in chronic kidney disease: beyond phosphorus control. <i>Nefrologia</i> , 2015 , 35, 207-217	0.4	10
282	Haemodialysate: long neglected, difficult to optimize, may modify hard outcomes. <i>CKJ: Clinical Kidney Journal</i> , 2015 , 8, 576-9	4.5	5
281	The fate of triaged and rejected manuscripts. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 1947-50	4.3	5
280	Humble kidneys predict mighty heart troubles. Lancet Diabetes and Endocrinology, the, 2015, 3, 489-91	18.1	14
279	Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances. <i>CKJ: Clinical Kidney Journal</i> , 2015 , 8, 686-9	4.5	3
278	Association between the IL17RA rs4819554 polymorphism and reduced renal filtration rate in the Spanish RENASTUR cohort. <i>Human Immunology</i> , 2015 , 76, 75-8	2.3	15
277	TNF-related weak inducer of apoptosis (TWEAK) regulates junctional proteins in tubular epithelial cells via canonical NF- B pathway and ERK activation. <i>Journal of Cellular Physiology</i> , 2015 , 230, 1580-93	7	33
276	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 1999-2010	12.7	164
275	Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development. <i>PLoS ONE</i> , 2015 , 10, e0136863	3.7	37
274	Therapeutic approaches to diabetic nephropathybeyond the RAS. <i>Nature Reviews Nephrology</i> , 2014 , 10, 325-46	14.9	131
273	Next-generation phosphate binders: focus on iron-based binders. <i>Drugs</i> , 2014 , 74, 863-77	12.1	20
272	Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. <i>Kidney International</i> , 2014 , 85, 103-11	9.9	102
271	Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 293-303	6.9	11
270	Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. <i>Journal of Proteomics</i> , 2014 , 96, 92-102	3.9	101
269	Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 1275-84	4.3	41
268	Deferasirox nephrotoxicity-the knowns and unknowns. <i>Nature Reviews Nephrology</i> , 2014 , 10, 574-86	14.9	45
267	CKD hotspots around the world: where, why and what the lessons are. A CKJ review series. <i>CKJ:</i> Clinical Kidney Journal, 2014 , 7, 519-23	4.5	37

266	IL-17A is a novel player in dialysis-induced peritoneal damage. <i>Kidney International</i> , 2014 , 86, 303-15	9.9	63
265	Urine 2DE proteome analysis in healthy condition and kidney disease. <i>Electrophoresis</i> , 2014 , 35, 2634-4	1 3.6	15
264	Spanish guidelines for the management of autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29 Suppl 4, iv95-105	4.3	43
263	Unilateral ureteral obstruction: beyond obstruction. International Urology and Nephrology, 2014, 46, 76	5 <u>-7</u> 7.6	116
262	Osteoprotegerin and kidney disease. <i>Journal of Nephrology</i> , 2014 , 27, 607-17	4.8	29
261	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 1563-70	4.3	94
260	Differential effects of oral and intravenous l-carnitine on serum lipids: is the microbiota the answer?. <i>CKJ: Clinical Kidney Journal</i> , 2014 , 7, 437-41	4.5	6
259	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. <i>Lancet, The</i> , 2014 , 383, 1831-43	40	250
258	3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes. <i>Archives of Toxicology</i> , 2014 , 88, 597-60	1 8 5.8	15
257	Gremlin activates the Smad pathway linked to epithelial mesenchymal transdifferentiation in cultured tubular epithelial cells. <i>BioMed Research International</i> , 2014 , 2014, 802841	3	33
256	TWEAK and the progression of renal disease: clinical translation. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29 Suppl 1, i54-i62	4.3	78
255	Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 232-9	4.3	67
254	The authors reply:. Kidney International, 2014, 85, 1240	9.9	
253	Bicarbonate therapy, phosphate binders, and risk for vascular calcification. <i>Kidney International</i> , 2014 , 86, 1056	9.9	5
252	Individualization of dialysate calcium concentration according to baseline pre-dialysis serum calcium. <i>Blood Purification</i> , 2014 , 38, 224-33	3.1	13
251	Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation. <i>Clinical Science</i> , 2014 , 127, 19-31	6.5	37
250	Application of the new cholesterol guidelines. New England Journal of Medicine, 2014, 371, 79	59.2	6
249	p-cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 56-64	4.3	65

(2013-2014)

248	Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis. <i>American Journal of Physiology - Renal Physiology</i> , 2014 , 307, F75-85	4.3	13
247	Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. <i>Journal of the American Heart Association</i> , 2014 , 3,	6	95
246	Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2014 , 23, 93-100	3.5	16
245	Mitochondria-targeted therapies for acute kidney injury ŒRRATUM. <i>Expert Reviews in Molecular Medicine</i> , 2014 , 16,	6.7	1
244	Mitochondria-targeted therapies for acute kidney injury. <i>Expert Reviews in Molecular Medicine</i> , 2014 , 16, e13	6.7	64
243	Role of chemokines in proteinuric kidney disorders. Expert Reviews in Molecular Medicine, 2014, 16, e3	6.7	20
242	CXCL16 in kidney and cardiovascular injury. Cytokine and Growth Factor Reviews, 2014, 25, 317-25	17.9	49
241	Macrophages and recently identified forms of cell death. <i>International Reviews of Immunology</i> , 2014 , 33, 9-22	4.6	12
240	TWEAK promotes peritoneal inflammation. <i>PLoS ONE</i> , 2014 , 9, e90399	3.7	17
239	Translational study of the Notch pathway in hypertensive nephropathy. <i>Nefrologia</i> , 2014 , 34, 369-76	1.5	9
238	Defining protein-energy wasting syndrome in chronic kidney disease: prevalence and clinical implications. <i>Nefrologia</i> , 2014 , 34, 507-19	1.5	20
237	Molecular mediators of favism-induced acute kidney injury. Clinical Nephrology, 2014 , 81, 203-9	2.1	12
236	Cortisol levels are associated with mortality risk in hemodialysis patients. <i>Clinical Nephrology</i> , 2014 , 82, 247-56	2.1	8
235	Increasing serum calcium levels and recent return from transplantation as clues to the tuberculous nature of refractory peritoneal dialysis peritonitis. <i>Journal of Postgraduate Medicine</i> , 2014 , 60, 200-1	0.8	
234	Designing a method to assess and improve the quality of healthcare in Nephrology by means of the Delphi technique. <i>Nefrologia</i> , 2014 , 34, 158-74	1.5	2
233	Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enema. <i>Journal of Bone and Mineral Metabolism</i> , 2013 , 31, 703-7	2.9	7
232	TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013 , 1832, 1744-55	6.9	71
231	Fibrosis: a key feature of Fabry disease with potential therapeutic implications. <i>Orphanet Journal of Rare Diseases</i> , 2013 , 8, 116	4.2	82

230	Fn14 in podocytes and proteinuric kidney disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013 , 1832, 2232-43	6.9	41
229	MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple. <i>Cytokine and Growth Factor Reviews</i> , 2013 , 24, 23-40	17.9	32
228	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort. <i>Gene</i> , 2013 , 527, 670-2	3.8	8
227	The demise of calcium-based phosphate binders. <i>Lancet, The</i> , 2013 , 382, 1232-4	40	14
226	Calcineurin inhibitors recruit protein kinases JAK2 and JNK, TLR signaling and the UPR to activate NF- B -mediated inflammatory responses in kidney tubular cells. <i>Toxicology and Applied Pharmacology</i> , 2013 , 272, 825-41	4.6	29
225	Pulmonary hypertension in CKD. American Journal of Kidney Diseases, 2013, 61, 612-22	7.4	91
224	Progress in the development of animal models of acute kidney injury and its impact on drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2013 , 8, 879-95	6.2	26
223	The use of echocardiography in observational clinical trials: the EURECA-m registry. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 19-23	4.3	11
222	Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 505-17	4.3	64
221	The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response. <i>Laboratory Investigation</i> , 2013 , 93, 812-24	5.9	36
220	Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis. <i>CKJ: Clinical Kidney Journal</i> , 2013 , 6, 510-2	4.5	0
219	Bisphenol a in chronic kidney disease. <i>International Journal of Nephrology</i> , 2013 , 2013, 437857	1.7	29
218	Subclinical versus overt obesity in dialysis patients: more than meets the eye. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28 Suppl 4, iv175-81	4.3	20
217	TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease. <i>Frontiers in Immunology</i> , 2013 , 4, 447	8.4	37
216	Connective tissue growth factor is a new ligand of epidermal growth factor receptor. <i>Journal of Molecular Cell Biology</i> , 2013 , 5, 323-35	6.3	44
215	DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells. <i>Epigenetics</i> , 2013 , 8, 66-78	5.7	42
214	Parathyroid hormone-related protein protects renal tubuloepithelial cells from apoptosis by activating transcription factor Runx2. <i>Kidney International</i> , 2013 , 83, 825-34	9.9	15
213	TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation. <i>Journal of Pathology</i> , 2013 , 231, 480-94	9.4	42

212	Laser therapy in metabolic syndrome-related kidney injury. <i>Photochemistry and Photobiology</i> , 2013 , 89, 953-60	3.6	11
211	Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 12024-9	11.5	391
210	A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. <i>BMC Systems Biology</i> , 2013 , 7, 110	3.5	28
209	A polymeric nanomedicine diminishes inflammatory events in renal tubular cells. <i>PLoS ONE</i> , 2013 , 8, e5	1992	31
208	Identification of a potent endothelium-derived angiogenic factor. <i>PLoS ONE</i> , 2013 , 8, e68575	3.7	3
207	Osteoprotegerin in exosome-like vesicles from human cultured tubular cells and urine. <i>PLoS ONE</i> , 2013 , 8, e72387	3.7	40
206	Hyperlipidemia-associated renal damage decreases Klotho expression in kidneys from ApoE knockout mice. <i>PLoS ONE</i> , 2013 , 8, e83713	3.7	43
205	Recommendations on reintroduction of agalsidase Beta for patients with fabry disease in europe, following a period of shortage. <i>JIMD Reports</i> , 2013 , 8, 51-6	1.9	8
204	Prevalence of protein-energy wasting syndrome and its association with mortality in haemodialysis patients in a centre in Spain. <i>Nefrologia</i> , 2013 , 33, 495-505	1.5	46
203	Vitamin D and proteinuria: a critical review of molecular bases and clinical experience. <i>Nefrologia</i> , 2013 , 33, 716-26	1.5	25
202	First episodes of peritoneal infection: description and prognostic factors. <i>Nefrologia</i> , 2013 , 33, 316-24	1.5	1
201	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012 , 42, 1027-36	4.6	131
200	Risk in dosing regimens for 25-OH vitamin D supplementation in chronic haemodialysis patients. <i>Nephron</i> , 2012 , 121, c112-9	3.3	5
199	Haematuria: the forgotten CKD factor?. Nephrology Dialysis Transplantation, 2012, 27, 28-34	4.3	61
198	Notch3 and kidney injury: never two without three. <i>Journal of Pathology</i> , 2012 , 228, 266-73	9.4	20
197	High prevalence of winter 25-hydroxyvitamin D deficiency despite supplementation according to guidelines for hemodialysis patients. <i>Clinical and Experimental Nephrology</i> , 2012 , 16, 945-51	2.5	15
196	Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled. <i>International Urology and Nephrology</i> , 2012 , 44, 1731-44	2.3	30
195	A role for the membrane proteome in human chronic kidney disease erythrocytes. <i>Translational Research</i> , 2012 , 160, 374-83	11	14

194	Normal and pathologic concentrations of uremic toxins. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 1258-70	12.7	578
193	Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus. <i>Molecular Genetics and Metabolism</i> , 2012 , 105, 525-7	3.7	24
192	Proteome changes in the myocardium of experimental chronic diabetes and hypertension: role of PPAREn the associated hypertrophy. <i>Journal of Proteomics</i> , 2012 , 75, 1816-29	3.9	29
191	Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?. <i>BMC Nephrology</i> , 2012 , 13, 21	2.7	4
190	TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. <i>Kidney International</i> , 2012 , 81, 1098-107	9.9	55
189	Gremlin is a downstream profibrotic mediator of transforming growth factor-beta in cultured renal cells. <i>Nephron Experimental Nephrology</i> , 2012 , 122, 62-74		33
188	Phosphate: a stealthier killer than previously thought?. Cardiovascular Pathology, 2012, 21, 372-81	3.8	53
187	Klotho modulates the stress response in human senescent endothelial cells. <i>Mechanisms of Ageing and Development</i> , 2012 , 133, 647-54	5.6	48
186	Oxidative stress, macrophage infiltration and CD163 expression are determinants of long-term renal outcome in macrohematuria-induced acute kidney injury of IgA nephropathy. <i>Nephron Clinical Practice</i> , 2012 , 121, c42-53		34
185	Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. <i>Kidney International</i> , 2012 , 82, 652-63	9.9	57
184	Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. <i>PLoS ONE</i> , 2012 , 7, e47440	3.7	15
183	Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 302, F647-57	4.3	120
182	Monocyte subpopulations and cardiovascular risk in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2012 , 8, 362-9	14.9	117
181	Blood Pressure. Clinical Therapeutics, 2012, 34, e12-e13	3.5	
180	GSK3, snail, and adhesion molecule regulation by cyclosporine A in renal tubular cells. <i>Toxicological Sciences</i> , 2012 , 127, 425-37	4.4	30
179	Undetectable serum calcidiol: not everything that glitters is gold. <i>CKJ: Clinical Kidney Journal</i> , 2012 , 5, 37-40	4.5	5
178	Fabry disease: the many faces of a single disorder. CKJ: Clinical Kidney Journal, 2012, 5, 379-82	4.5	3
177	AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 175-84	6.9	86

176	HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II. <i>Laboratory Investigation</i> , 2012 , 92, 32-45	5.9	47
175	The human plasma lipidome. New England Journal of Medicine, 2012, 366, 668; author reply 668-9	59.2	5
174	Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 478-81	4.3	15
173	Dual-specificity phosphatases are implicated in severe hyperplasia and lack of response to FGF23 of uremic parathyroid glands from rats. <i>Endocrinology</i> , 2012 , 153, 1627-37	4.8	9
172	AG490 promotes HIF-1\(\text{\textit{B}}\)ccumulation by inhibiting its hydroxylation. <i>Current Medicinal Chemistry</i> , 2012 , 19, 4014-23	4.3	12
171	Targeting chemokines in proteinuria-induced renal disease. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 833-45	6.4	19
170	Vitamin D receptor activation and cardiovascular disease. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27 Suppl 4, iv17-21	4.3	38
169	Antioxidants in kidney diseases: the impact of bardoxolone methyl. <i>International Journal of Nephrology</i> , 2012 , 2012, 321714	1.7	37
168	Phosphorus and nutrition in chronic kidney disease. International Journal of Nephrology, 2012, 2012, 59	7 6.9 5	37
167	Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 1042-9	4.3	106
166	Klotho, phosphate and inflammation/ageing in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27 Suppl 4, iv6-10	4.3	63
165	Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 2720-33	4.3	8
164	Angiotensin II contributes to renal fibrosis independently of Notch pathway activation. <i>PLoS ONE</i> , 2012 , 7, e40490	3.7	33
163	Acute kidney injury transcriptomics unveils a relationship between inflammation and ageing. <i>Nefrologia</i> , 2012 , 32, 715-23	1.5	10
162	Is it or is it not a pathogenic mutation? Is it or is it not the podocyte?. <i>Journal of Nephropathology</i> , 2012 , 1, 152-4	0.6	11
161	Start-up of a clinical sample processing, storage and management platform: organisation and development of the REDinREN Biobank. <i>Nefrologia</i> , 2012 , 32, 28-34	1.5	2
160	Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. <i>Nature Reviews Nephrology</i> , 2011 , 8, 141-50	14.9	40
159	Delayed graft function and cotrimoxazole. <i>Transplantation Proceedings</i> , 2011 , 43, 2502-4	1.1	3

158	Acute renal failure associated to paroxysmal nocturnal haemoglobinuria leads to intratubular haemosiderin accumulation and CD163 expression. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 3408-	.14:3	50
157	Paricalcitol for reduction of albuminuria in diabetes. <i>Lancet, The</i> , 2011 , 377, 635-6, author reply 636-7	40	12
156	Tenofovir nephrotoxicity: 2011 update. AIDS Research and Treatment, 2011, 2011, 354908	2.3	168
155	Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. Journal of Translational Medicine, 2011 , 9, 13	8.5	100
154	Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. <i>Proteomics - Clinical Applications</i> , 2011 , 5, 281-8	3.1	14
153	Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. <i>Proteomics - Clinical Applications</i> , 2011 , 5, 233-40	3.1	16
152	Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 2567-71	4.3	135
151	Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 1797-802	4.3	138
150	The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. <i>Kidney International Supplements</i> , 2011 , 1, 6-9	6.3	45
149	The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?. <i>Kidney International Supplements</i> , 2011 , 1, 17-20	6.3	8
148	TWEAK, a multifunctional cytokine in kidney injury. <i>Kidney International</i> , 2011 , 80, 708-18	9.9	76
147	The inflammatory cytokines TWEAK and TNF#educe renal klotho expression through NF B . <i>Journal of the American Society of Nephrology: JASN</i> , 2011 , 22, 1315-25	12.7	257
146	Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 785-92	6.9	77
145	The meaning of urinary creatinine concentration. <i>Kidney International</i> , 2011 , 79, 791	9.9	6
144	Animal models of cardiovascular diseases. <i>Journal of Biomedicine and Biotechnology</i> , 2011 , 2011, 49784	1	226
143	Major pathways of the reno-cardiovascular link: the sympathetic and renin-angiotensin systems. <i>Kidney International Supplements</i> , 2011 , 1, 13-16	6.3	9
142	The complexity of the cardio-renal link: taxonomy, syndromes, and diseases. <i>Kidney International Supplements</i> , 2011 , 1, 2-5	6.3	18
141	Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease. <i>Kidney International Supplements</i> , 2011 , 1, 10-12	6.3	38

140	Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?. <i>Kidney International Supplements</i> , 2011 , 1, 21-23	6.3	31
139	Acute renal failure in patient treated with anti-tumour necrosis factor alpha. <i>Nefrologia</i> , 2011 , 31, 484-8	31.5	1
138	Calcific uremic arteriolopathy while on cinacalcet. <i>Journal of Postgraduate Medicine</i> , 2011 , 57, 51-2	0.8	5
137	TWEAK and the kidney: the dual role of a multifunctional cytokine. <i>Advances in Experimental Medicine and Biology</i> , 2011 , 691, 323-35	3.6	4
136	Peritoneal dialysis and kidney transplant. A two-way ticket in an integrated renal replacement therapy model. <i>Nefrologia</i> , 2011 , 31, 441-8	1.5	5
135	PPAR-lagonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. Laboratory Investigation, 2010 , 90, 1517-32	5.9	55
134	Obstructive renal injury: from fluid mechanics to molecular cell biology. <i>Research and Reports in Urology</i> , 2010 , 2, 41-55	1.3	16
133	Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-IIndependent process. <i>PLoS ONE</i> , 2010 , 5, e14145	3.7	49
132	NF-kappaB in renal inflammation. Journal of the American Society of Nephrology: JASN, 2010, 21, 1254-6	2 12.7	385
131	Reality and desirePin the care of advanced chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2010 , 3, 431-5	4.5	5
130	Suppressors of cytokine signaling abrogate diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 763-72	12.7	131
129	End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 769-75	4.3	76
128	Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes. <i>Diabetes</i> , 2010 , 59, 1292-301	0.9	44
127	The expanding spectrum of biological actions of vitamin D. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 2850-65	4.3	73
126	BASP1 promotes apoptosis in diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 610-21	12.7	63
125	Peritonitis due to Microbacterium sp in a patient on cycler peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2010 , 30, 669-70	2.8	9
124	TNF superfamily: a growing saga of kidney injury modulators. <i>Mediators of Inflammation</i> , 2010 , 2010,	4.3	63
123	Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clinical Journal of the American Society of Nephrology: CJASN, 2010 , 5, 2220-8	6.9	94

122	Tyrphostins as potential therapeutic agents for acute kidney injury. <i>Current Medicinal Chemistry</i> , 2010 , 17, 974-86	4.3	20
121	Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 4103-6	4.3	36
120	Unravelling fibrosis: two newcomers and an old foe. Nephrology Dialysis Transplantation, 2010, 25, 349	2-54.3	14
119	BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 1098-108	4.3	79
118	Regulation of Vascular and Renal Cells by Common Mediators in Health and Disease: Role of the Renin Angiotensin System in the Pathophysiology of Hypertension and Cardiovascular Disease 2010 , 49-63		
117	Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 397, 576-9	3.4	12
116	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. <i>Kidney International</i> , 2010 , 78, 1275-80	9.9	31
115	New paradigms in cell death in human diabetic nephropathy. <i>Kidney International</i> , 2010 , 78, 737-44	9.9	42
114	Familial C4B deficiency and immune complex glomerulonephritis. <i>Clinical Immunology</i> , 2010 , 137, 166-7	759	10
113	TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. <i>PLoS ONE</i> , 2010 , 5, e8955	3.7	77
112	A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury. <i>PLoS ONE</i> , 2009 , 4, e6634	3.7	27
111	The MIF receptor CD74 in diabetic podocyte injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 353-62	12.7	81
110	CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1513-26	12.7	86
109	Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. <i>Kidney International</i> , 2009 , 76, 1268-76	9.9	92
108	Gliotoxin inhibits neointimal hyperplasia after vascular injury in rats. <i>Journal of Vascular Research</i> , 2009 , 46, 278-89	1.9	8
107	Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 110-8	6.9	93
106	Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. <i>Cardiovascular Research</i> , 2009 , 83, 586-94	9.9	40
105	Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity. <i>Kidney International</i> , 2009 , 75, 227-34	9.9	41

(2008-2009)

104	TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 3089-96	4.3	80
103	Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009 , 297, H2109-19	5.2	79
102	Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 1716-23	6.9	63
101	Inhibition of p38-MAPK potentiates cisplatin-induced apoptosis via GSH depletion and increases intracellular drug accumulation in growth-arrested kidney tubular epithelial cells. <i>Toxicological Sciences</i> , 2009 , 111, 413-23	4.4	20
100	Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 2061-8	9.4	74
99	Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 3329-42	5.6	74
98	Considering TWEAK as a target for therapy in renal and vascular injury. <i>Cytokine and Growth Factor Reviews</i> , 2009 , 20, 251-8	17.9	42
97	Patogfiesis de la malnutricifi en pacientes en dillsis con fifasis en los aspectos ma espec fi cos de la dillsis peritoneal. <i>Dialisis Y Trasplante</i> , 2009 , 30, 57-62		
96	Estrategias en la profilaxis y el tratamiento de la malnutricifi en dillsis peritoneal: un problema infradiagnosticado. <i>Dialisis Y Trasplante</i> , 2009 , 30, 93-99		
95	Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 278-85	4.3	53
94	Taming Apoptosis in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2009 , 29, 45-48	2.8	2
93	Trail and kidney disease. Frontiers in Bioscience - Landmark, 2009, 14, 3740-9	2.8	12
92	Sistemas y soluciones de dillsis peritoneal 2009 , 149-164		
91	Alkalinization potentiates vascular calcium deposition in an uremic milieu. <i>Journal of Nephrology</i> , 2009 , 22, 647-53	4.8	27
90	A search for cyclophilin-A gene variants in cyclosporine A-treated renal transplanted patients. <i>Clinical Transplantation</i> , 2008 , 22, 722-9	3.8	15
89	Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. <i>Molecular Genetics and Metabolism</i> , 2008 , 93, 112-28	3.7	375
88	Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 160	o 4 ₹	142
87	Mechanisms of renal apoptosis in health and disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1634-42	12.7	168

86	Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. <i>Kidney International</i> , 2008 , S88-93	9.9	17
85	Benefits of preserving residual renal function in peritoneal dialysis. <i>Kidney International</i> , 2008 , S42-51	9.9	95
84	The death ligand TRAIL in diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 904-14	12.7	87
83	Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. <i>Kidney International</i> , 2008 , 74, 585-95	9.9	93
82	Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. <i>Nature Clinical Practice Nephrology</i> , 2008 , 4, 327-36		57
81	3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 3307-15	4.3	15
80	Severe everolimus-associated pneumonitis in a renal transplant recipient. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 3353-5	4.3	35
79	The cytokine TWEAK modulates renal tubulointerstitial inflammation. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 695-703	12.7	145
78	ACE gene polymorphism and the prognosis and treatment of overt diabetic nephropathy. <i>Nature Clinical Practice Nephrology</i> , 2008 , 4, 472-3		2
77	A slit in podocyte death. Current Medicinal Chemistry, 2008, 15, 1645-54	4.3	17
76	Bcl-xL Prevents Peritoneal Dialysis Solution-Induced Leukocyte Apoptosis. <i>Peritoneal Dialysis International</i> , 2008 , 28, 48-52	2.8	7
75	Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation. <i>PLoS ONE</i> , 2008 , 3, e3959	3.7	40
74	Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. <i>Pharmaceutical Research</i> , 2008 , 25, 2447-61	4.5	53
73	Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2008 , 13, 11-32	5.4	143
72	TWEAKing renal injury. Frontiers in Bioscience - Landmark, 2008, 13, 580-9	2.8	9
71	Bcl-xL prevents peritoneal dialysis solution-induced leukocyte apoptosis. <i>Peritoneal Dialysis International</i> , 2008 , 28 Suppl 5, S48-52	2.8	4
70	TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. <i>Frontiers in Bioscience - Landmark</i> , 2007 , 12, 3648-55	2.8	43
69	Endovascular repair of mycotic aneurysms of the aorta: an alternative to conventional bypass surgery in patients with acute sepsis. <i>Scandinavian Journal of Infectious Diseases</i> , 2007 , 39, 268-71		6

68	Emphysematous pyelonephritis in dialysis patient after embolization of failed allograft. <i>Urology</i> , 2007 , 70, 372.e17-9	1.6	11
67	Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 916-22	9.4	107
66	Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. <i>Stroke</i> , 2006 , 37, 2044-53	6.7	79
65	Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapya Spanish multicentre experience. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21 Suppl 2, ii51-5	4.3	62
64	Modulation of renal tubular cell survival: where is the evidence?. <i>Current Medicinal Chemistry</i> , 2006 , 13, 449-54	4.3	20
63	3,4-DGE is important for side effects in peritoneal dialysis what about its role in diabetes. <i>Current Medicinal Chemistry</i> , 2006 , 13, 2695-702	4.3	17
62	Peritoneal defencelessons learned which apply to diabetes complications. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21 Suppl 2, ii12-5	4.3	7
61	Lethal activity of FADD death domain in renal tubular epithelial cells. <i>Kidney International</i> , 2006 , 69, 220	155:51	8
60	Cytokine cooperation in renal tubular cell injury: the role of TWEAK. <i>Kidney International</i> , 2006 , 70, 1750) 989	117
59	3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. <i>Kidney International</i> , 2005 , 68, 1303-11	9.9	48
58	Role of Bcl-xL in paracetamol-induced tubular epithelial cell death. <i>Kidney International</i> , 2005 , 67, 592-6	0 519	32
57	Long-term blood pressure control prevents oxidative renal injury. <i>Antioxidants and Redox Signaling</i> , 2005 , 7, 1285-93	8.4	25
56	3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. <i>Diabetes</i> , 2005 , 54, 2424	-9 .9	73
55	Tubular cell apoptosis and cidofovir-induced acute renal failure. Antiviral Therapy, 2005, 10, 185-90	1.6	27
54	Tubular Cell Apoptosis and Cidofovir-Induced Acute Renal Failure. <i>Antiviral Therapy</i> , 2005 , 10, 185-190	1.6	73
53	Will Modulation of Cell Death Increase PD Technique Survival?. <i>Peritoneal Dialysis International</i> , 2004 , 24, 105-114	2.8	12
52	Paracetamol-induced renal tubular injury: a role for ER stress. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 380-9	12.7	115
51	Tight blood pressure control decreases apoptosis during renal damage. <i>Kidney International</i> , 2004 , 65, 811-22	9.9	11

50	Modulation of survival in osteoblasts from postmenopausal women. <i>Bone</i> , 2004 , 35, 170-7	4.7	19
49	Persistent proteinuria up-regulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells. <i>American Journal of Pathology</i> , 2004 , 164, 1817-26	5.8	49
48	Will modulation of cell death increase PD technique survival?. <i>Peritoneal Dialysis International</i> , 2004 , 24, 105-14	2.8	4
47	Inhibition of Caspases Improves Bacterial Clearance in Experimental Peritonitis. <i>Peritoneal Dialysis International</i> , 2003 , 23, 123-126	2.8	19
46	Targeting apoptosis in acute tubular injury. Biochemical Pharmacology, 2003, 66, 1589-94	6	58
45	Regulation of apoptosis by lethal cytokines in human mesothelial cells. <i>Kidney International</i> , 2003 , 64, 321-30	9.9	23
44	Bcl-xL overexpression protects from apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells. <i>Kidney International</i> , 2003 , 64, 181-91	9.9	27
43	Expression of Smac/Diablo in tubular epithelial cells and during acute renal failure. <i>Kidney International</i> , 2003 , S52-6	9.9	25
42	Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. <i>Kidney International</i> , 2003 , S21-6	9.9	57
41	Staining for cell death. Lancet, The, 2003, 361, 1748; author reply 1748	40	1
40	Staining for cell death. <i>Lancet, The</i> , 2003 , 361, 1748; author reply 1748 Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 3072-80	40	114
	Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. <i>Journal of the American</i>		
40	Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 3072-80 Inhibition of caspases improves bacterial clearance in experimental peritonitis. <i>Peritoneal Dialysis</i>	12.7	114
40	Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 3072-80 Inhibition of caspases improves bacterial clearance in experimental peritonitis. <i>Peritoneal Dialysis International</i> , 2003 , 23, 123-6 Pseudomonas oryzihabitans peritonitis in a patient on continuous ambulatory peritoneal dialysis.	12.7 2.8	114
40 39 38	Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 3072-80 Inhibition of caspases improves bacterial clearance in experimental peritonitis. <i>Peritoneal Dialysis International</i> , 2003 , 23, 123-6 Pseudomonas oryzihabitans peritonitis in a patient on continuous ambulatory peritoneal dialysis. <i>Clinical Microbiology and Infection</i> , 2002 , 8, 607-8 Role of endogenous vascular endothelial growth factor in tubular cell protection against acute	12.7 2.8 9.5	114 14 5
40 39 38 37	Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 3072-80 Inhibition of caspases improves bacterial clearance in experimental peritonitis. <i>Peritoneal Dialysis International</i> , 2003 , 23, 123-6 Pseudomonas oryzihabitans peritonitis in a patient on continuous ambulatory peritoneal dialysis. <i>Clinical Microbiology and Infection</i> , 2002 , 8, 607-8 Role of endogenous vascular endothelial growth factor in tubular cell protection against acute cyclosporine toxicity. <i>Transplantation</i> , 2002 , 74, 1618-24 Peritoneal Dialysis Retardation of Progression of Advanced Renal Failure. <i>Peritoneal Dialysis</i>	12.7 2.8 9.5	114 14 5
4039383736	Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 3072-80 Inhibition of caspases improves bacterial clearance in experimental peritonitis. <i>Peritoneal Dialysis International</i> , 2003 , 23, 123-6 Pseudomonas oryzihabitans peritonitis in a patient on continuous ambulatory peritoneal dialysis. <i>Clinical Microbiology and Infection</i> , 2002 , 8, 607-8 Role of endogenous vascular endothelial growth factor in tubular cell protection against acute cyclosporine toxicity. <i>Transplantation</i> , 2002 , 74, 1618-24 Peritoneal Dialysis Retardation of Progression of Advanced Renal Failure. <i>Peritoneal Dialysis International</i> , 2002 , 22, 239-242 Contribution of apoptotic cell death to renal injury. <i>Journal of Cellular and Molecular Medicine</i> , 2001	12.7 2.8 9.5 1.8	114 14 5 34 32

32	Nephrology forum: apoptotic regulatory proteins in renal injury. <i>Kidney International</i> , 2000 , 58, 467-85	9.9	64
31	Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. <i>Kidney International</i> , 2000 , 57, 969-81	9.9	113
30	Renal cell loss through cell suicide. <i>Kidney International</i> , 2000 , 58, 2235-6	9.9	10
29	Antiplatelet therapy alters iron requirements in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2000 , 36, 80-7	7.4	7
28	Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. Journal of the American Society of Nephrology: JASN, 2000 , 11, 1266-1277	12.7	94
27	Role and regulation of apoptotic cell death in the kidney. Y2K update. <i>Frontiers in Bioscience - Landmark</i> , 2000 , 5, D735-49	2.8	12
26	The study of apoptosis in spine pathology. <i>Spine</i> , 1999 , 24, 500	3.3	2
25	Role of cytokines in the response to erythropoietin in hemodialysis patients. <i>Kidney International</i> , 1998 , 54, 1337-43	9.9	116
24	Cyclosporine A induces apoptosis in murine tubular epithelial cells: role of caspases. <i>Kidney International</i> , 1998 , 68, S25-9	9.9	54
23	3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. <i>Circulation Research</i> , 1998 , 83, 490-500	15.7	350
22	Circulating endothelial cells in sickle cell anemia. <i>New England Journal of Medicine</i> , 1998 , 338, 1162; author reply 1162-3	59.2	5
21	Concentrated ascitic fluid reinfusion in cirrhotic patients: a simplified method. <i>American Journal of Kidney Diseases</i> , 1997 , 29, 392-8	7.4	5
20	Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells. <i>Kidney International</i> , 1996 , 49, 1064-70	9.9	44
19	Glomerular up-regulation of EIIIA and V120 fibronectin isoforms in proliferative immune complex nephritis. <i>Kidney International</i> , 1996 , 50, 908-19	9.9	10
18	Undiagnosed hepatitis C virus infection in hemodialysis patients: value of HCV RNA and liver enzyme levels. <i>Kidney International</i> , 1996 , 50, 2027-31	9.9	28
17	Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. <i>Kidney International</i> , 1995 , 47, 1419	9- 3 .5j	140
16	ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. <i>Kidney International</i> , 1995 , 48, 1778-91	9.9	93
15	Epithelial differentiation of metanephric mesenchymal cells after stimulation with hepatocyte growth factor or embryonic spinal cord. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994 , 91, 5286-90	11.5	43

14	Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. <i>American Journal of Kidney Diseases</i> , 1993 , 22, 822-8	7.4	72
13	Cefazolin-induced neurotoxicity. <i>Clinical Infectious Diseases</i> , 1992 , 14, 624	11.6	3
12	Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits. <i>Nephron</i> , 1992 , 60, 248	3.3	10
11	Presence of circulating antibodies against brush border antigens (Fx1A) in a patient with membranous nephropathy and bilateral pyeloureteral stenosis. Comparison with idiopathic membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 1992 , 7, 293-9	4.3	2
10	Fatal coma and superimposed acute renal failure in a diabetic peritoneal dialysis patient following myelography. <i>Nephron</i> , 1992 , 60, 381-2	3.3	
9	Effect of recombinant human growth hormone in a postpediatric hemodialysis patient with delayed growth. <i>American Journal of Nephrology</i> , 1992 , 12, 471-3	4.6	1
8	Salmonella enteritidis empyema complicating lupus pleuritis. <i>Postgraduate Medical Journal</i> , 1991 , 67, 778-9	2	5
7	Involvement of lipid mediators in the pathogenesis of experimental nephrosis in rats: its pharmacological modulation. <i>Renal Failure</i> , 1991 , 13, 95-101	2.9	4
6	Persistent anemia after successful kidney graft. <i>Nephron</i> , 1991 , 59, 158-9	3.3	3
5	Role of platelet-activating factor in adriamycin-induced nephropathy in rats. <i>European Journal of Pharmacology</i> , 1987 , 138, 119-23	5.3	21
4	Apoptosis in the Kidney240-249		1
3	Nephrotoxicity291-310		1
2	Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naWe and COVID-19 recovered individuals		8
1	Evaluation of the impact of an intradialytic exercise programme on sarcopaenia in very elderly haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> ,	4.5	3